
The FlyPharma Conference Europe wrapped up for another year on 6 June, returning with an expanded roster of speakers who …

UK drug watchdog NICE has chosen to issue final guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS …

Just as it ramps up its cancer-fighting efforts, Eli Lilly has revealed that its Senior Vice President and President of …

Axovant has announced reinforcements to its management team with two new additions, snatching up Allergan’s current Chief Medical Officer Dr …

Eli Lilly has announced that its oral JAK inhibitor Olumiant (baricitinib) has received FDA approval for the treatment of moderately-to-severely …

Five more deaths have been reported to the FDA in patients using intragastric balloon systems, meaning that 12 total deaths …

Nektar Therapeutics has seen its share price devastated after revealing disappointing trial data for its candidate NKTR-214 in combination with …

Janssen took the opportunity at the American Society of Clinical Oncology (ASCO) annual event to present promising new Phase 2 …

Roche made an underwhelming impact at the American Society of Clinical Oncology (ASCO) annual event in Chicago, after revealing data …

The decision to award the EMA headquarters to Amsterdam was a contentious one, not least because the vote had to …

Amgen and Novartis have announced that their newly FDA-approved treatment for migraines has received a recommendation from the CHMP, generally …

Up until present, no studies had shown that immunotherapies could offer potential treatment for men with prostate cancer; however, at …

The fact that Celgene is currently sailing through choppy waters is no secret to anyone within the industry, it’s facing …

The first day of June – time for another top ten run-down. It’s been a week somewhat characterised by trial …

Israeli biopharmaceutical firm is celebrating the approval in the US of Consensi, a combo of the calcium channel blocker amlodipine …